Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07431177 · ClinicalTrials.gov registry record · Phase 2
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
A Phase 2 study of Non-segmental Vitiligo, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 210
- Enrollment target
- 6
- Study locations
NCT07431177 is a Phase 2 study of Non-segmental Vitiligo that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 210 participants, above the 184-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target (14% higher). The trial reports 6 study locations across 5 states.
The verdict
NCT07431177, a Phase 2 study of Non-segmental Vitiligo, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 210 participants
- Enrollment target
- 6
- Study locations
Study Summary
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GIA632
Study Locations (6)
New South Wales
- Novartis Investigative Site - Sydney
- Novartis Investigative Site - Waitara
Alabama
- Cahaba Derm and skin hlth ctr 27 - Birmingham
Florida
- Miami Derm and Laser Institute - Miami
Michigan
- Revival Research Institute - Troy
Ontario
- Novartis Investigative Site - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-03-09 |
| Est. Completion | 2030-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07431177
The ClinicalTrials.gov registry entry for NCT07431177 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 184-participant average among 5 other Non-segmental Vitiligo trials with a reported enrollment target (14% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-segmental Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07431177 reports 6 study locations spanning 5 distinct geographic areas - top geographies include New South Wales, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT07431177 about?
NCT07431177 is a clinical study titled "A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo". The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.
What is the current status of trial NCT07431177?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2026-03-09. Estimated completion is 2030-02-14.
What conditions does trial NCT07431177 study?
This clinical trial studies the following conditions: Non-segmental Vitiligo.
What interventions are being tested in trial NCT07431177?
The interventions under investigation include: Placebo (DRUG), GIA632 (DRUG).
Who is sponsoring clinical trial NCT07431177?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07431177 being conducted?
This trial has 6 study locations across Alabama, Florida, Michigan, New South Wales, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-segmental Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
RECRUITING · Phase 2
-
An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
COMPLETED · Phase 2
-
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.